Batlivala & Karani

RESULT UPDATE

MID CAP Share Data

Share Data				
Reuters code PIDI.BC				
Bloomberg code	Р	IDI IN		
Market cap. (US\$ m		1,409		
6M avg. daily turnov	5\$ mn)	0.5		
Issued shares (mn)		506		
Target price (Rs)			150	
Performance (%)	1M	3M	12M	
Absolute	(14)	(15)	33	
Relative	(5)	(1)	19	

Valuation ratios

Yr to 31 Mar	FY11E	FY12E
EPS (Rs)	6.6	7.5
+/- (%)	11.9	13.3
PER(x)	19.1	16.9
PBV(x)	5.7	4.8
Dividend/Yield (%)	1.6	2.0
EV/Sales (x)	2.8	2.3
EV/EBITDA(x)	13.8	11.7
Major shareholde	rs (%)	
Promoters		71
FIIs		9
MFs		8
BFSI's		1

11

Financial highlights

Public & Others

Pidilite Industries

Price: Rs 126

BSE Index: 17,776

09 February 2011

Maintain Outperformer

3QFY11 Result – Impressive quarter, though margin concerns surface

Results were above expectations as the top line recorded an impressive growth of 28% YoY, aided by strong growth in both the consumer and industrial segments. The consumer segment benefitted from a late Diwali, which pushed some of the second quarter sales to the third quarter. The industrial segment was helped by a significant pick up of ~70% in exports. Margins improved on a YoY basis but as expected, were suppressed on a sequential basis following the run up in prices of crude based derivatives. Higher other income along with a reduction in interest outgo, following the repurchase of its NCDs, led to an increase of 25% in the reported PAT.

Although the margins improved on a YoY basis, the increasing cost of crude based derivatives (used as raw material), is bound to put some pressure on the margins in FY12. The company has the pricing power to pass on input price inflation partially, and is expected to exercise that in 4QFY11. The A&P spend, which stood at ~3% in this quarter, can also increase marginally during the upcoming World Cup 2011 and the IPL 4 season.

The synthetic elastomer plant should be operational by the end of FY12. It will incur an additional capex of Rs 1.4 bn, which is likely to be funded from its internal accruals. The plant is expected to commence commercial operations from the beginning of FY13, with an initial capacity of 20,000 TPA. The utilisation is expected to be low in the first year and gradually increase afterwards.

Taking into account the expected pressure from input price inflation and the initial expenses on the elastomer plant, we are downgrading our FY12 earnings by 5%. The revised target price, based on 20x FY12E stands at Rs 150. The stock currently trades at 19.1x FY11E and 16.9x FY12E our revised estimates. Maintain Outperformer.

(Rs mn) 3Q	QFY10	3QFY11	YoY (%)	9MFY10	9MFY11	YoY (%)	FY10	FY11E	YoY (%)	FY12E	YoY (%)
Net Sales	4,608	5,884	27.7	14,829	17,970	21.2	19,297	22,869	18.5	27,070	18.4
EBITDA	872	1,134	29.9	3,217	3,805	18.3	3,860	4,632	20.0	5,363	15.8
EBITDA margin (%)	18.9	19.3	_	21.7	21.2	_	20.0	20.3	_	19.8	_
Other income	73	107	46.4	198	291	47.4	272	383	40.7	449	17.3
Interest	74	52	(30.0)	228	221	(3.1)	286	268	(6.2)	238	(11.3)
Depreciation	108	111	2.5	349	330	(5.3)	464	465	0.2	528	13.5
РВТ	763	1,078	41.2	2,838	3,546	24.9	3,382	4,281	26.6	5,046	17.9
Extraordinary exp. (income)	8	(6)	(176.2)	92	22	(75.9)	93	22	(76.2)	_	NA
PBT after extraordinary iter	n 755	1,084	43.7	2,746	3,524	28.3	3,289	4,259	29.5	5,046	18.5
Tax (incl deferred tax)	117	233	100.1	405	779	92.4	398	942	137.0	1,262	33.9
Reported PAT	682	851	24.8	2,385	2,745	15.1	2,935	3,317	13.0	3,785	14.1
Adjusted PAT	646	844	30.6	2,434	2,767	13.7	2,984	3,339	11.9	3,785	13.3
Adjusted PAT margin (%)	14.0	14.3	_	16.4	15.4	_	15.5	14.6	_	14.0	_
Adjusted EPS (Rs)	1.3	1.7	30.6	4.8	5.5	13.7	5.9	6.6	11.9	7.5	13.3



B&K RESEARCH

Income Statement				
Yr end 31 Mar (Rs mn	h) FY09	FY10	FY11E	FY12E
Net sales	17,611	19,297	22,869	27,070
Growth (%)	14.7	9.6	18.5	18.4
Operating expenses	(15, 267)	(15, 437)	(18, 237)	(21,706)
Operating profit	2,344	3,860	4,632	5,363
EBITDA	2,344	3,860	4,632	5,363
Growth (%)	(7.5)	64.7	20.0	15.8
Depreciation	(472)	(464)	(465)	(528)
Other income	239	272	383	449
EBIT	2,111	3,668	4,550	5,284
Interest paid	(318)	(286)	(268)	(238)
Pre-tax profit	1,793	3,382	4,281	5,046
(before non-recurring item	s)			
Non-recurring items	(161)	(93)	(22)	0
Pre-tax profit (after non-recurring items)	1,632	3,289	4,259	5,046
Tax (current + deferred)	(168)	(398)	(942)	(1,262)
Net profit (before Minority Interest, Pref Dividend, et		2,891	3,317	3,785
Reported PAT	1,464	2,935	3,317	3,785
Prior period adjustments	0	44	0	0
Adjusted net profit	1,624	2,984	3,339	3,785
Growth (%)	(12.2)	83.7	11.9	13.3

Balance Sheet				
Yr end 31 Mar (Rs mn)	FY09	FY10	FY11E	FY12E
Cash & marketable sec.	1,447	2,955	3,619	4,356
Other current assets	5,782	5,908	7,650	8,871
Investments	2,231	2,483	2,483	2,483
Net fixed assets	6,733	6,949	6,705	7,207
Total assets	16,193	18,294	20,456	22,916
Current liabilities	2,836	4,279	5,089	5,712
Total debt	5,580	4,214	3,730	3,580
Other non-current liabilitie	s 441	415	415	415
Total liabilities	8,857	8,908	9,234	9,707
Share capital	253	506	506	506
Reserves & surplus	7,083	8,880	10,716	12,703
Shareholders' funds	7,336	9,386	11,222	13,209
Total equity & liab.	16,193	18,294	20,456	22,916
Capital employed	13,357	14,015	15,368	17,204

Cash Flow Statemer	nt			
Yr end 31 Mar (Rs mn)	FY09	FY10	FY11E	FY12E
Pre-tax profit	1,632	3,289	4,259	5,046
Depreciation	459	456	450	498
Chg in working capital	348	950	(1, 228)	(893)
Total tax paid	(150)	(423)	(942)	(1, 262)
Cash flow from oper. (a)	2,289	4,316	2,540	3,389
Capital expenditure	(1,722)	(672)	(206)	(1,000)
Chg in investments	(783)	(2,700)	(175)	(135)
Other investing activities	852	1,598	800	800
Cash flow from inv. (b) (1,653)	(1,773)	419	(335)
Free cash flow (a+b)	636	2,543	2,959	3,055
Equity raised/(repaid)	(0)	224	0	0
Debt raised/(repaid)	554	(1, 366)	(485)	(150)
Dividend (incl. tax)	(506)	(518)	(885)	(1, 180)
Other financing activities	(899)	(1, 822)	(1, 100)	(1, 122)
Cash flow from fin. (c)	(851)	(3,482)	(2,470)	(2,453)
Net chg in cash (a+b+c)	(215)	(940)	489	602

Key Ratios				
Yr end 31 Mar (%)	FY09	FY10	FY11E	FY12E
EPS (Rs)	3.2	5.9	6.6	7.5
EPS growth	(12.2)	83.7	11.9	13.3
Book NAV/ share (Rs)	14.5	18.5	22.2	26.1
Dividend/ share (Rs)	0.9	1.5	2.0	2.5
Dividend payout ratio	31.1	29.7	35.3	39.0
Tax	10.3	12.1	22.1	25.0
EBITDA margin	13.3	20.0	20.3	19.8
EBIT margin	12.0	19.0	19.9	19.5
RoCE	16.7	26.8	31.0	32.4
Net debt/Equity	56.3	13.4	1.0	(5.9)


Valuations				
Yr end 31 Mar (x)	FY09	FY10	FY11E	FY12E
PER	39.3	21.4	19.1	16.9
PCE	30.4	18.5	16.8	14.8
Price/Book	8.7	6.8	5.7	4.8
Yield (%)	0.7	1.2	1.6	2.0
EV/Net sales	3.9	3.4	2.8	2.3
EV/EBITDA	29.0	16.8	13.8	11.7

Du Pont Analysis – ROE						
Yr end 31 Mar (x)	FY09	FY10	FY11E	FY12E		
Net margin (%)	9.2	15.5	14.6	14.0		
Asset turnover	1.2	1.1	1.2	1.2		
Leverage factor	2.2	2.1	1.9	1.8		
Return on equity (%)	23.6	35.7	32.4	31.0		

Kaustav Kakati kaustav.kakati@bksec.com +91 -120-460 5622 Vikash Singh vikash.singh@bksec.com +91-120-460 5613

Analyst Declaration: We, Kaustav Kakati & Vikash Singh, hereby certify that the views expressed in this report accurately reflect our personal views about the subject securities and issuers. We also certify that no part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendation or view expressed in this report.

B&K Universe Profile



B&K Securities is the trading name of Batlivala & Karani Securities India Pvt. Ltd.

B&K Investment Ratings:

1. **BUY:** Potential upside of > +25% (absolute returns)

0 to +25%

- 2. OUTPERFORMER:
- 3. UNDERPERFORMER: 0 to -25%
- 4. **SELL:** Potential downside of < -25% (absolute returns)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, print, publishing, photocopying, recording or otherwise without the permission of Batlivala & Karani Securities India Pvt. Ltd. Any unauthorized act in relation to all or any part of the material in this publication may call for appropriate statutory proceedings.

The information contained herein is confidential and is intended solely for the addressec(s). Any unauthorized access, use, reproduction, disclosure or dissemination is prohibited. This information does not constitute or form part of and should not be construed as, any offer for sale or subscription of or any invitation to offer to buy or subscribe for any securities. The information and opinions on which this communication is based have been complied or arrived at from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, correctness and are subject to change without notice. Batlivala & Karani Securities India P Ltd and/ or its clients may have positions in or options on the securities mentioned in this report or any related investments, may effect transactions or may buy, sell or offer to buy or sell such securities or any related investments. Recipient/s should consider this report only for secondary market investments and as only a single factor in making their investment decision. The information enclosed in the report has not been vetted by the compliance department due to the time sensitivity of the information/document. Some investments discussed in this report have a high level of volatility. High volatility investments may experience sudden and large falls in their value causing losses when the investment is realized. Those losses may equal your original investment. Some investments may not be readily realizable and it may be difficult to sell or realize those investments, similarly it may prove difficult for you to obtain reliable information about the value, risks to which such an investment is exposed. Neither B&K Securities nor any of its affiliates shall assume any legal liability or responsibility for any incorrect, misleading or altered information contained herein.

B & K SECURITIES INDIA PRIVATE LTD.

Equity Research Division: City Ice Bldg, 298, Ground/1st Floor, Perin Nariman Street, Behind RBI, Fort, Mumbai - 400 001, India. Tel.: 91-22-4031 7000, Fax: 91-22-2263 5020/30. Registered Office: Room No. 3/4, 7 Lyons Range, Kolkata - 700 001. Tel.: 91-33-2243 7902.

B&K Research is also available on Bloomberg <BNKI>, Thomson First Call & Investext.